Aquestive 2025 Q3 Earnings Wider Loss Amid Revenue Decline

Aquestive Therapeutics (AQST) reported Q3 2025 earnings that fell short of expectations, . The company maintained full-year guidance despite the setbacks, signaling continued investment in pre-launch preparations for Anaphylm.

Revenue

, . Manufacturing and supply revenue rose to $11.47 million, driven by higher demand for Sympazan and Suboxone, , . The performance highlights uneven growth across segments, with core manufacturing offsetting declines in licensing.

Earnings/Net Income

The company’s net loss widened to $15.45 million, , a 7.7% increase in losses year-over-year. The EPS shortfall and rising operational costs underscore ongoing financial pressure, with the stock’s post-earnings trajectory reflecting broader market skepticism.

Price Action

AQST shares fell 1.32% in the latest trading day, , . The stock’s volatility contrasts with mixed historical performance following revenue announcements.

Post-Earnings Price Action Review

, . . While the strategy yielded positive returns in half of the quarters, inconsistent results highlight the need for caution in tactical investing.

CEO Commentary

. , . Strengthened liquidity and global regulatory expansion were highlighted as key enablers for long-term growth.

Guidance

. .

Additional News

1. FDA Regulatory Progress, 2026, with no advisory committee meeting required, accelerating potential U.S. launch timelines.

2. Patent Expansion, reinforcing its competitive position.

3. AQST-108 Development, targeting alopecia areata, .

Guidance

, 2025, . .